亚甲基四氢叶酸还原酶C677T基因多态性与肝癌肝动脉化学治疗栓塞术疗效的关系

目的]探讨亚甲基四氢叶酸还原酶(MTHFR)C677T基因多态性与原发性肝癌患者肝动脉化学治疗栓塞术(TACE)疗效的关系.方法]给125例原发性肝癌患者行TACE治疗,其中63例给予复方碘油加顺铂(DDP)、吡柔比星(THP)和丝裂霉素(MMC)混悬剂灌注;62例给予复方碘油加DDP,THP及5-氟脲嘧啶(5-FU)混悬剂.经行2次TACE治疗后进行临床疗效评价.采用Real-time PCR检测MTHFRC677T基因多态性,分析不同基因型与TACE治疗疗效的关系.结果]125例患者的总有效率为35.2%,其中复方碘油混合DDP,THP及MMC治疗组有效率为38.1%,复方碘油混合DDP,THP及5-FU治疗组有效率为32.3%,两者间差异无统计学意义(P=0.494).MTHFR C677T基因多态性与2种TACE治疗均无相关性.结论]MTHFR C677T基因多态性对肝癌TACE常用药物的敏感性无影响.

Relationship of curative effects between methylenetetrahydrofolate reductase C677T polymorphism and transarterial chemoembolization in primary hepatocellular carcinoma

OBJECTIVE To evaluate the relationship of curative effects between methylenetetrahydrofolate reductase（MTHFR） C677T polymorphism and transarterial chemoembolization（TACE） in primary hepatocellular carcinoma（HCC）.METHODS 125 patients with HCC were treated with TACE,in witch 63 patients were administrated by TACE with perfusing lipiodol mixed with cisplatin（DDP）,pirarubicin（THP） and mitomycin（MMC） and 62 patients with perfusing lipiodol mixed DDP,THP and 5-fluorouracil（5-FU）,and clinical response was evaluated after 2 cycles.MTHFR C677T polymorphisms were determined were analyzed by real-time quantitative polymerase chain reaction to analyze the association between genetic polymorphisms and clinical responses.RESULTS The total curative effective rate was 35.% 125 patients with HCC,and 38.1% and 32.3% in two groups,respectively,with no statistically significant difference（P for trend=0.494）.CONCLUSION MTHFR C677T polymorphism has no significant role in response to TACE treatment in HCC patients.